Results 141 to 150 of about 38,837 (270)

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan, Christian Pifl, Thomas Steinkellner   +2 more
wiley   +1 more source

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy

Neuropsychiatric Disease and Treatment, 2019
Kristen Ward,1 Leslie Citrome2 1Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA; 2Department of Psychiatry and Behavioral Science, New York Medical College, Valhalla, NY, USA Abstract: The purpose of this
Ward K, Citrome L
doaj  

Second-Generation Antipsychotics in Adolescent Psychiatric Patients: Metabolic Effects and Impact of an Early Weight Change to Predict Longer Term Weight Gain

, 2018
Frederik Vandenberghe, Alexandra Najar-Giroud, Laurent Holzer, Philippe Conus, Chin B. Eap, Anne‐Emmanuelle Ambresin   +5 more
openalex   +2 more sources

Propensity Score Estimation to Address Calendar Time-Specific Channeling in Comparative Effectiveness Research of Second Generation Antipsychotics

, 2020
Stacie B. Dusetzina, Christina Mack, Til Stürmer‎   +2 more
openalex   +1 more source

Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults ...
Ting Zhou, Huilin Tang, Bingyu Zhang, Dazheng Zhang, Yiwen Lu, Lu Li, Jiajie Chen, Yong Chen, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East

Neuropsychiatric Disease and Treatment, 2015
Sulaiman Alkhadhari,1 Nasser Al Zain,2 Tarek Darwish,3 Suhail Khan,4 Tarek Okasha,5 Hisham Ramy,5 Talaat Matar Tadros6 1Kuwait Center for Mental Health, Safat, Kuwait; 2Al Amal Complex for Mental Health Hospital, Dammam, Saudi Arabia; 3Behavioural ...
Alkhadhari S, Al Zain N, Darwish T, Khan S, Okasha T, Ramy H, Tadros TM   +6 more
doaj  

Weight Gain and Treatment Interruptions with Second-Generation Oral Antipsychotics: Analysis of Patients with Schizophrenia or Bipolar I Disorder [PDF]

, 2021
Michael J. Doane, Leona Bessonova, Kathleen Mortimer, Harry Cheng, Gregory Donadio, Thomas Brecht, Amy K. O’Sullivan, Hannah Cummings, David McDonnell, Jonathan M. Meyer   +9 more
openalex   +1 more source

D1/D5 receptor activation promotes long‐term potentiation and synaptic tagging/capture in hippocampal area CA2

The FEBS Journal, EarlyView.
Activation of dopamine receptor D1 (D1R) stimulates PKA and ERK pathways via dissociation of stimulatory and olfactory G protein alpha subunits (Gαs/olf). PKA relieves striatal‐enriched protein tyrosine phosphatase (STEP) inhibition of ERK, promoting cyclic adenosine monophosphate response element‐binding protein (CREB)‐driven transcription of ...
Kevin Chua, Yee Song Chong, Sreedharan Sajikumar   +2 more
wiley   +1 more source

Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies

, 2021
Miquel Bernardo, Fernando Rico‐Villademoros, Clemente García‐Rizo, Rosa Rojo, Ricardo Gómez‐Huelgas   +4 more
openalex   +1 more source

Parkinson's Disease and Salivary Issues: A Survey

Gerodontology, EarlyView.
ABSTRACT Background Salivary dysfunction, including xerostomia and drooling, is common in Parkinson's disease and further impairs oral health and quality of life, which are already compromised in this population. Their effective management demands deeper insight into the complexity of salivary dysfunction.
Beau D. M. van Dijk, Merel C. Verhoeff, Niels van der Aa, Frank Lobbezoo   +3 more
wiley   +1 more source